Charting A Course in the Treatment of Crohn's Disease: Case Studies, Controversies and Future Directions

Faculty

Needs Statement

The optimal management of patients with moderately to severely active Crohn’s disease represents a balance between minimizing the risk of medication-related serious adverse events while simultaneously sustaining long-term remission, improving patient quality of life, and ultimately modifying the long-term natural disease course. Current treatment paradigms may not be achieving these goals and may be exposing patients to increased risks. Emerging data on new
therapies and novel approaches to the treatment of these patients may eventually provide clinicians with potentially safer alternatives to the traditional step-up paradigm. Physicians are challenged to integrate the latest clinical trial results into current evidence-based recommendations and incorporate these data into routine clinical care. This activity will use a case-based format to address clinical controversies and new directions in care in order to optimize outcomes for patients with moderate to severe Crohn’s disease.

Target Audience

This activity has been designed to meet the educational needs of physicians, nurses, pharmacists and health care professionals involved in the care of patients with Crohn’s disease.

Please note if you particpated in the live version you are not eligible to receive credit for this webcast.

Objectives

At the end of this educational activity, participants should be able to:
1. Describe the epidemiology and diagnosis of Crohn’s disease;
2. Evaluate current treatment algorithm guidelines in the management of patients with Crohn’s disease;
3. Assess the benefit-risk profiles of new treatment options for Crohn’s disease;
4. Formulate the integration of new therapies into treatment strategies for improved patient outcomes.

Accreditation

CME
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Kentucky College of Medicine and OptumHealth Education. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this educational activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

CPE
The University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned ACPE # 022-999-09-006-H01-P and will award 1.50 contact hour(s) (0.15 CEU(s)) of continuing pharmacy education credit in states that recognize ACPE providers.

Statements of credit will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. The College complies with the Accreditation Standards for Continuing Pharmacy Education.

ANCC
OptumHealth Education is an approved provider of continuing nursing education by the Utah Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. The participant will be awarded 1.50 contact hours of credit for completion of supplemental materials.

Faculty Disclosure

Dr. Hanauer serves as a consultant to Abbott Laboratories, Bristol-Myers Squibb Company, Centocor, Inc., Elan Pharmaceuticals, Inc., Ferring Pharmaceuticals, Genentech, Inc., Millenium Pharmaceuticals, Inc., P&G Pharmaceuticals, Prometheus Therapeutics & Diagnostics, Salix Pharmaceuticals, Inc., Shire, and UCB S.A.; he receives grant/research Support from Abbott Laboratories, Bristol-Myers Squibb Company, Centocor, Inc., Elan Pharmaceuticals, Inc., Ferring Pharmaceuticals, Genentech, Inc., P&G Pharmaceuticals, Prometheus Therapeutics & Diagnostics, Salix Pharmaceuticals, Inc., Shire, and UCB S.A.; and serves on the speakers bureau for Centocor, Inc., Ferring Pharmaceuticals, P&G Pharmaceuticals, Prometheus Therapeutics & Diagnostics, Salix Pharmaceuticals, Inc., and UCB S.A.  Dr Hanauer does not intend to discuss unapproved/investigative use of commercial products/devices.

Dr. Abreu serves on the advisory board for Elan Pharmaceuticals, Inc.; serves as a consultant to Elan Pharmaceuticals, Inc., P&G Pharmaceuticals; receives grant/research Support from P&G Pharmaceuticals; and serves on the speakers bureau for Elan Pharmaceuticals, Inc., P&G Pharmaceuticals. Dr. Abreu does not intend to discuss unapproved/investigative use of commercial products/devices.

Dr. Feagan serves as a consultant to Synta Pharmaceuticals Corp., Millennium Pharmaceuticals, Inc., Schering-Plough Canada Inc., Celltech, Centocor, Inc., Elan Pharmaceuticals, Inc., Biogen Idec, Janssen-Ortho Inc., PDL BioPharma, Inc., Isis Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Santarus, Inc., Schering-Plough Corporation, Bristol-Meyers Squibb Company, Celgene Corporation, CombinatoRx, UCB S. A., Napo Pharmaceuticals, Abbott Laboratories, P&G Pharmaceuticals, Osiris Therapeutics, Inc., Berlex, AstraZeneca, Gene Logic, Cerimon Pharmaceuticals, Tioga Pharmaceuticals, Inc., Merck Serono International, Genetech, Inc., Tillotts Pharma AG; receives grant/research support from Schering-Plough Corporation, Otsuka, Millennium Pharmaceuticals, Inc., Tillotts Pharma AG, Abbott Laboratories, PDL BioPharma, Inc., Boehringer Ingelheim, Novartis, Centocor, Berlex, Synta Pharmaceuticals Corp., Schering-Plough Canada Inc., Elan Pharmaceuticals, Inc., Biogen Idec, UCB Pharma, Bristol-Myers Squibb Company, P&G Pharmaceuticals, Napo Pharmaceuticals, Osiris Therapeutics, Inc., and Genetech, Inc; serves on the speakers bureau for AstraZeneca; and has other financial relationships with PDL BioPharma, Inc., AstraZeneca, Elan Pharmaceuticals, Inc., Biogen Idec, Celltech, Synta Pharmaceuticals Corp., Schering-Plough Canada Inc., Celegene Corporation, and Novartis
Dr. Feagan intends to discuss unapproved/investigative use of commercial products/devices.

Other personnel who were involved in the development of content for this activity have disclosed that they have no relevant financial relationships.

Activity Sponsorship

This activity is jointly sponsored by the University of Kentucky and OptumHealth Education. Supported by an unrestricted educational grant from Elan Pharmaceuticals.